Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment
Open accessThe DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrine diseases causing infertility in women of childbearing age. It is characterized by hyperandrogenemia (HA), chronic anovulation, and polycystic ovary morphology (PCOM). Most women with PCOS have metabolic abnormalities. Sex hormone-binding globulin (SHBG), a transport carrier that binds estrogen and androgens and regulates their biological activity, is usually used as an indicator of hyperandrogenism in women with PCOS. Low serum SHBG levels are considered a biomarker of metabolic abnormalities and are associated with insulin resistance (IR), HA, and abnormal glucose and lipid metabolism in PCOS patients. SHBG is also related to the long-term prognosis of PCOS, whereas SHBG gene polymorphism is associated with PCOS risk. In addition, the administration of metformin (MET), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), thiazolidinediones (TZDs), compound oral contraceptives (COCs), as well as nutrient supplements such as inositol (MI), vitamin D, and synbiotics can regulate SHBG levels to ameliorate PCOS complications and improve prognosis. This review focuses on the interaction between SHBG and various PCOS complications as well as the regulation of SHBG by various drugs and nutrients and its therapeutic effects on PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, increased plasma insulin levels also increase the amount of circulating free androgens by reducing the production of Sex Hormone-Binding Globulin (SHBG) in the liver [15].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., International PCOS Network, Andersen, M., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey256 · Cited by 1,593
Adipose tissue dysfunction as determinant of obesity-associated metabolic complications
Longo, M., Zatterale, F., Naderi, J., Parrillo, L., Formisano, P., Raciti, G. A., Beguinot, F., & Miele, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092358 · Cited by 1,575
The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention
Holick, M. F. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9424-1 · Cited by 1,511
Lifestyle changes in women with polycystic ovary syndrome
Lim, S. S., Hutchison, S. K., Van Ryswyk, E., Norman, R. J., Teede, H. J., & Moran, L. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007506.pub4 · Cited by 725
Using human genetics to understand the disease impacts of testosterone in men and women
The Endometrial Cancer Association Consortium, Ruth, K. S., Day, F. R., Tyrrell, J., Thompson, D. J., Wood, A. R., Mahajan, A., Beaumont, R. N., Wittemans, L., Martin, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0751-5 · Cited by 720 · cited 9×
“In terms of reproduction, IR stimulates the production of ovarian androgens through insulin and aggravates HA with a reduction in SHBG.114 In terms of metabolism, IR is associated with impaired glucose tolerance, T2DM, and cardiovascular disease.”
BackgroundInfluentialPLYMATE, S. R., MATEJ, L. A., JONES, R. E., & FRIEDL, K. E. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-460 · Cited by 693 · cited 8×
“In terms of reproduction, IR stimulates the production of ovarian androgens through insulin and aggravates HA with a reduction in SHBG.114 In terms of metabolism, IR is associated with impaired glucose tolerance, T2DM, and cardiovascular disease.”
BackgroundInfluentialTranscriptional regulation of hepatic lipogenesis
Wang, Y., Viscarra, J., Kim, S.-J., & Sul, H. S. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4074 · Cited by 646
Potential role and therapeutic interests of myo-inositol in metabolic diseases
Croze, M. L., & Soulage, C. O. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.011 · Cited by 578
Cited by
Items 101–121 of 121
Aljaddoa, N. A., Ahmed, M. K., & Shahid, S. (2026) · Indus journal of bioscience research. · doi:10.70749/ijbr.v4i5.3088
DeepETD: a novel deep-learning based model for endogenous metabolite target discovery
Xu, Z., Wang, X., Yang, X., Yuan, X., Zhu, K., Min, X., Xiao, W., Xu, H., Luo, C., & Zhang, H. (2026) · Targetome · doi:10.48130/targetome-0026-0024
Assessment of Corin and Neprilysin in Diverse Polyendocrine Metabolic Ovarian Syndrome Presentations
Fleih, M. H., El-Yaseen, H. D., & Al-Naddawi, A. M. (2026) · Journal of the Faculty of Medicine Baghdad · doi:10.32007/jfacmedbaghdad3314
UNLOCKING THE POTENTIAL OF RESVERATROL IN MANAGING POLYCYSTIC OVARY SYNDROME: A SYSTEMATIC REVIEW
Bhaskaran, D., ANGAPPAN, S., & SEBASTIAN, S. (2026) · INDIAN DRUGS · doi:10.53879/id.63.06.15459
Khaleel, A. S., Al-Fatlawi, A. C. Y., & Abood, W. G. (2026) · Asian Pacific Journal of Cancer Care · doi:10.31557/apjcc.2026.11.4.501
Varra, F., Theodosis‐Nobelos, P., Varra, V., & Varras, M. N. (2026) · Medicina · doi:10.3390/medicina62081445
Exploring on the Hyperinsulinism Management in Women with Polycystic Ovary Syndrome
de Medeiros, S. F., Yamamoto, M. M. W., Jacomeli, J., Soares, J. M., Maciel, G. A. R., & Baracat, E. C. (2026) · Journal of Gynecology and Obstetrics · doi:10.11648/j.jgo.20261403.12
Polat, S., & Şimşek, Y. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12498-z
Jeyavelkumaran, R., Keerthivasan, N., & Saravanan, M. D. (2026) · Folia Microbiologica · doi:10.1007/s12223-026-01577-0
Mechanisms of traditional Chinese medicine in treatment of polycystic ovary syndrome: A review
塗士彥, 武露明, Cheng, T., Tao, J., Fan, X., Wang, Y., & Wang, Y. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.09.001
Repurposing metabolic drugs: Anti-diabetic and anti-obesity agents with potential in cancer therapy
Uti, D. E., Almohaimeed, H. M., Aggad, W. S., Egbung, J. E., Anthony, B. O., Ogar, R. O., & Alum, E. U. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100747
Kowalczyk, K., Gałczyńska, D., Herman, J., Czyż, M., Kowalczyk, D., Drosdzol-Cop, A. B., & Franik, G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1975667
Xie, C., 庄, 明., Huang, J., & Guo, Y. (2026) · Metabolites · doi:10.3390/metabo16100725
Cooper, I. D., Petagine, L., Cooper, N., Soto-Mota, A., Edwards, K., Kraev, I., Lange, S., & Kyriakidou, Y. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2040016
Cera, N., Pinto, J., Maccarone, M. T., & Pignatelli, D. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16100512
Ben, O. J., Ighodaro, O. M., Akinrinmola, A. O., & Igbekele, B. M. (2026) · Journal of Biochemistry International · doi:10.56557/jobi/2026/v13i111187
Pilcová, R. (2026) · Česko-slovenská pediatrie · doi:10.55095/cspediatrie2026/007
Meghana, K., Devi, C. A., Poongavanam, S. S., Kirubakaran, D., & Manikandan, C. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100606
Pradhan, S., & Gopalakrishnan, A. V. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12967-5
Han, Y., & Gao, S. (2026) · International Journal of Endocrinology · doi:10.1155/ije/8944835
Nutritional and lifestyle management of polycystic ovary syndrome PCOSs: A comprehensive review
Qasim, E., Habib, H., Saeed, K., Kubra, K. T., Musheer, I., & Basit, A. (2026) · Forensic Insights and Health Sciences Bulletin · doi:10.56770/fihsb2026424
Metadata
- Authors
- Xing, C., Zhang, J., Zhao, H., & He, B.
- Affiliations
- Sheng Jing Hospital (CN)
- Corresponding author
- He, Bing
- Venue
- International Journal of Women's Health
- Publisher
- Informa UK Limited
- Published
- 2022-02
- Volume
- Volume 14
- Pages
- 91-105
- ISSN
- 1179-1411 (ISSN-L)
- PMC
- PMC8818772
- OpenAlex
- W4210722375
- Cited by
- 118
- References
- 126
- Citations by year
- 2026: 33 · 2025: 31 · 2024: 23 · 2023: 26 · 2022: 5
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Women s Health (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Natural Science Foundation of China (81570765)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- polycystic ovary syndrome, sex hormone-binding globulin, hyperandrogenemia, insulin resistance, metabolic abnormalities, metformin, GLP-1 receptor agonists, thiazolidinediones, oral contraceptives, myo-inositol, vitamin D, synbiotics, PCOS treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.